|
Jun 5
|
AstraZeneca completes Fusion Pharmaceuticals acquisition
|
|
May 31
|
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
|
|
May 29
|
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca
|
|
May 10
|
Fusion Pharmaceuticals doses first subject in prostate cancer trial
|
|
May 9
|
Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer
|
|
May 7
|
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates
|
|
May 2
|
Fusion Pharmaceuticals Inc. (FUSN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Apr 26
|
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
|
|
Apr 25
|
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
|
|
Apr 23
|
Fusion Pharmaceuticals Inc. (FUSN) Ascends But Remains Behind Market: Some Facts to Note
|
|
Apr 17
|
Fusion Pharmaceuticals Inc. (FUSN) Stock Moves -0.09%: What You Should Know
|
|
Apr 11
|
Fusion Pharmaceuticals Inc. (FUSN) Flat As Market Gains: What You Should Know
|
|
Apr 11
|
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) is definitely on the radar of institutional investors who own 46% of the company
|
|
Apr 9
|
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
|
|
Mar 22
|
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates
|
|
Mar 20
|
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
|
|
Mar 20
|
Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca
|
|
Mar 20
|
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B
|
|
Mar 19
|
AstraZeneca acquires Fusion Pharmaceuticals in $2B deal
|
|
Mar 19
|
Stocks to Watch Tuesday: Super Micro, Fusion Pharmaceuticals, Nvidia, Unilever
|